Conmed Earnings Call: Trading Near-Term Pain for Growth

Conmed Corporation ((CNMD)) has held its Q4 earnings call. Read on for the main highlights of the call.

Conmed Balances Growth Investments With Near-Term Earnings Pressure in Latest Call

The latest earnings call from Conmed Corporation painted a picture of a company willing to trade short-term earnings softness for a more attractive long‑term profile. Management highlighted solid adjusted performance, accelerating growth in orthopedics, strong momentum in key platforms like AirSeal, Buffalo Filter, and BioBrace, and clear improvements in supply chain and cash generation. At the same time, they acknowledged a sharp decline in GAAP earnings, tariff-driven margin pressure, and earnings dilution from exiting the gastroenterology (GI) business. The tone was pragmatic: accept near-term pain to reposition the portfolio toward higher-margin, higher-growth franchises through 2026 and beyond.

Steady Revenue Growth in Q4 and Full Year

Conmed reported Q4 sales of $373.2 million, up 7.9% on a reported basis and 7.1% in constant currency, underscoring healthy demand across its portfolio. For the full year, revenue reached $1.375 billion, growing 5.2% reported and 5.1% in constant currency. While not explosive, this mid-single-digit top-line growth provides a stable base from which management is reshaping the business mix, particularly as they lean into higher-growth categories within orthopedics and advanced surgical technologies.

Adjusted Earnings Expand Despite GAAP Compression

On an adjusted basis, profitability continued to move in the right direction. Q4 adjusted EPS rose 6.7% year over year to $1.43, with adjusted net income up 6.2% to $44.4 million. For the full year, adjusted EPS increased 10.1% to $4.59, and adjusted net income likewise grew 10.1% to $143.1 million. These figures show that the underlying earnings engine is strengthening, even as GAAP results are pressured by special items and portfolio reshaping. For investors, the contrast between healthy adjusted growth and weaker GAAP numbers is central to understanding the current transition period.

Orthopedics Outperforms as Supply Chain Bottlenecks Ease

Orthopedics was a standout. Worldwide ortho sales grew 12.1% in Q4 and 5.5% for the full year in constant currency, outpacing company averages. U.S. orthopedics rose 6.6% in Q4, while international orthopedics surged 15.7%, pointing to robust global demand. Management also emphasized notable supply-chain progress: backorder value and SKUs on backorder are now at three-year lows. That improvement reduces friction in the sales channel and should support more reliable revenue capture in high-growth ortho segments going forward.

AirSeal Shows Strong Traction With Large White-Space Potential

The AirSeal insufflation platform continued to gain traction, being used in roughly 1.6 million procedures in 2025. Yet penetration in U.S. laparoscopy remains only around 6%–7%, suggesting substantial untapped market opportunity. Management sees AirSeal delivering high single-digit to low double-digit growth over the long term and highlighted a 10%–20% attachment rate on certain robotic surgery platforms. As robotic and minimally invasive procedures expand, AirSeal is positioned as a strategic growth driver with a long runway.

Buffalo Filter Rides Early-Stage Smoke Evacuation Adoption

Buffalo Filter, Conmed’s surgical smoke evacuation platform, is tied to a market management estimates at over $1 billion globally but still in early adoption. Regulatory momentum is building: 20 U.S. states, representing roughly 51% of the population, have enacted smoke-free operating room laws. In 2025, Conmed launched PlumeSafe x5, offering improvements in performance and noise, designed to strengthen its competitive stance. As hospitals respond to both regulation and staff safety concerns, Buffalo Filter gives Conmed a lever into a structurally growing niche.

BioBrace Gains Clinical Footing and Expands Use Cases

BioBrace continued to gain clinical adoption, now used in more than 70 distinct procedures, with notable traction in rotator cuff and foot and ankle surgeries. Management pointed to a randomized controlled trial involving 268 patients that is on pace to complete enrollment in 2026, with data publication expected in 2027—an important evidence milestone. The latest AAOS guidelines recommending augmentation in rotator cuff repair further support the use-case backdrop. Together, expanding indications and a strengthening clinical data pipeline make BioBrace a potentially powerful contributor to Conmed’s long-term ortho growth story.

Solid Cash Generation and Enhanced Capital Allocation Flexibility

Conmed’s cash generation supports its strategic pivot. Operating cash flow for FY2025 was $170.7 million, with Q4 contributing $46.3 million. The company ended the year with $40.8 million in cash and long-term debt of $834.2 million, translating to leverage of 2.9x. The board approved a $150 million share repurchase authorization and simultaneously suspended the roughly $25 million annual dividend. This shift redirects capital toward buybacks and broader capital allocation flexibility, signaling management’s preference to prioritize balance sheet management and EPS accretion over near-term income returns.

GAAP Earnings Hit by Special Items and Portfolio Actions

Beneath the strong adjusted metrics, GAAP earnings declined sharply, reflecting restructuring and portfolio actions. Q4 GAAP net income fell to $16.7 million from $33.8 million a year ago, with GAAP EPS dropping to $0.54 from $1.00. For the full year, GAAP net income was $47.1 million versus $132.4 million in 2024, and GAAP EPS slid to $1.51 from $4.25. Management attributed this deterioration primarily to special items and strategic moves such as the GI exit, underlining the extent to which reported earnings are being reshaped by one-time and transitional factors.

Tariff Headwinds Squeeze Margins

Tariffs are a significant drag on profitability. In Q4, Conmed’s adjusted gross margin fell 100 basis points to 56.6%, largely due to expected tariff impacts. Looking ahead to 2026, management expects incremental tariffs to represent about a 100–110 basis point headwind and reduce EPS by roughly $0.30–$0.35. Despite these pressures, the company is targeting net gross-margin expansion through pricing, mix, and operational improvements—an aggressive but key assumption behind its medium-term earnings framework.

GI Exit Brings Strategic Focus but Near-Term Dilution

Conmed’s decision to exit its GI product lines is central to its portfolio repositioning. The move is intended to sharpen focus on higher-margin, higher-growth areas like orthopedics and advanced surgical technologies. However, it comes with meaningful near-term earnings dilution: management estimates the GI exit will reduce 2026 adjusted EPS by approximately $0.45–$0.50. Investors will need to weigh this near-term drag against the longer-term benefits of a more focused portfolio.

U.S. General Surgery Faces Softness Amid Portfolio Pruning

U.S. general surgery sales slipped 0.4% in Q4, reflecting both softer market dynamics and deliberate portfolio pruning. Management pointed to the de-emphasis of OEM smoke evacuation SKUs and strategic exits within certain energy platforms as contributing factors. These actions aim to improve the portfolio’s overall profitability and strategic fit but are currently suppressing growth in parts of the general surgery segment.

Higher Operating Spend to Fund Growth Engines

Operating expenses are set to move higher as Conmed invests behind its chosen growth drivers. For 2026, the company guided adjusted SG&A to 38.0%–38.5% of sales, a step up driven by lower sales from the GI exit and increased commercial and support investments. Management expects Q1 to be the peak quarter for SG&A as a percentage of sales. While this adds near-term pressure on margins and EPS, it is framed as necessary spending to accelerate adoption of platforms like AirSeal, Buffalo Filter, and BioBrace.

Communication Missteps Spark Investor Questions

Analysts raised concerns over discrepancies between prior disclosures at a JPMorgan conference and the latest slides, particularly around organic revenue baselines and GI accounting. These inconsistencies led to follow-up clarifications and some investor confusion. While not affecting the underlying fundamentals, the episode highlights an execution risk in how Conmed communicates its evolving financial profile—an area investors will watch closely as the company navigates multiple moving pieces.

Debt Burden and Working Capital Remain Watch Points

Conmed’s leverage and working capital dynamics remain key risk markers. Long-term debt stands at $834.2 million, and though leverage at 2.9x is manageable, it leaves less room for macro or execution hiccups. Inventory days rose to 207 at year-end from 191 at quarter-end, which could weigh on working capital efficiency even as backorders improve. Management’s cash-flow guidance suggests they expect gradual improvement, but balance sheet and inventory discipline will be important for equity and credit investors alike.

Dividend Suspension Shifts Investor Profile

The decision to suspend the dividend in favor of share repurchases marks a notable change in shareholder return strategy. While the new $150 million repurchase authorization could support EPS and signal confidence in valuation, income-oriented investors may see the loss of the approximately $25 million annual dividend as a negative. The move aligns with management’s broader emphasis on long-term growth investments and balance-sheet flexibility, potentially skewing the shareholder base more toward growth and total-return investors rather than pure income seekers.

2026 Outlook: Moderate Top-Line Growth, Margin Rebuild Under Pressure

For 2026, Conmed guided reported revenue of $1.345–$1.375 billion, implying constant-currency organic growth of 4.5%–6% and a modest FX tailwind of up to 50 basis points. Despite tariffs expected to compress gross margin by about 100–110 basis points, management still targets a net gross-margin improvement of 50–100 basis points, reflecting confidence in mix and efficiency levers. Adjusted SG&A is projected at 38.0%–38.5% of sales and R&D at 4.5%–5.0%, with adjusted interest expense at $25–$27 million and an effective tax rate in the mid‑24% range. This framework drives adjusted EPS guidance of $4.30–$4.45, which already incorporates an estimated $0.45–$0.50 headwind from the GI exit and $0.30–$0.35 from tariffs, partially offset by about $0.10 of currency benefit. Management also forecasts operating cash flow of $145–$155 million, capex of $20–$30 million (roughly $125 million of free cash flow), and adjusted EBITDA of $255–$265 million. For Q1, they expect revenue of $308–$313 million and adjusted EPS of $0.80–$0.83, setting a baseline for the year’s trajectory.

In sum, Conmed’s earnings call underscored a deliberate transition: leveraging strong adjusted earnings, improving supply chains, and high-potential platforms in orthopedics and surgical technologies, while absorbing near-term hits from tariffs, a GI exit, higher operating spend, and weaker GAAP numbers. For investors, the story is less about immediate EPS upside and more about whether management can execute on its strategy to build a higher-margin, faster-growing business by 2026, while maintaining financial discipline in the face of debt, working-capital demands, and shifting capital-return policies.